Biotech investors will be closely watching results from Amgen on Wednesday. How should you game this stock into earnings?

Analysts widely believe the company continued to grapple with a weakened economy during the quarter, though price increases and a boost from overseas drug sales are expected to help Amgen's results.

Furthermore, the company's shares managed to avoid the volatility seen in other health care sectors as the debate over health care reform continues.

The quarter brought new developments for the company's next anticipated blockbuster, denosumab, or Prolia. On Monday, the FDA requested additional information on the drug, delaying the entire program for at least a few months.